The Committee to Assess the Health Implications of Perchlorate Ingestion \[National Academy of Sciences (NAS)\] released its final report \[[@b10-ehp0113-a0727b]\] in January 2005, recommending a reference dose (RfD) for perchlorate of 0.0007 mg/kg-day. In a commentary published online on 25 May 2005, [@b5-ehp0113-a0727b] criticized the adequacy of the NAS committee's scientific deliberations, mischaracterizing the studies reviewed by the committee and second-guessing its conclusions. [@b5-ehp0113-a0727b] implied that the U.S. Environmental Protections Agency's (EPA's) previous draft RfD of 0.00003 mg/kg-day ([@b12-ehp0113-a0727b])---and by inference the Massachusetts perchlorate risk assessment \[[@b9-ehp0113-a0727b]\] that mirrored the U.S. EPA's approach and which Ginsberg and Rice peer reviewed---is more scientifically defensible.

The NAS committee was composed of 15 leading physicians and scientists with combined range of expertise to evaluate every scientific aspect of the perchlorate database and of the U.S. EPA's assessment of that database. The makeup of this committee and its credentials are available on the NAS website ([@b9-ehp0113-a0727b]). The NAS committee studied and deliberated for more than 15 months before issuing its report. Those deliberations included three public meetings during which it accepted verbal and/or written comments from the U.S. EPA, other government agencies, industry, states, environmental groups, and attorneys. After careful study and consideration of the scientific studies that formed the basis for the [@b12-ehp0113-a0727b] draft RfD as well as the 2004 Massachusetts risk assessment ([@b8-ehp0113-a0727b]), the NAS committee considered

> several of the animal studies ... to be flawed in their design and execution. Conclusions based on those studies, particularly the neurodevelopmental studies, were not supported by the results of the studies.

Although [@b5-ehp0113-a0727b] implied that the NAS committee should have considered the threshold for measurable iodine uptake inhibition "adverse" and that the NAS inadvertently left out the "A" in NOAEL (no observed adverse effect level), the committee decisively stated that "inhibition of iodide uptake by the thyroid clearly is not an adverse effect." The committee carefully considered the issue of a NOEL (no observed effect level) and a NOAEL. Based on a clinical study of patients receiving perchlorate long term, the NAS established the NOAEL as 0.4 mg/kg-day (57 times higher than its identified NOEL).

[@b5-ehp0113-a0727b] further expressed concerns regarding perchlorate in breast milk and the subsequent possibility of decreased breast milk iodine, citing [@b7-ehp0113-a0727b] and [@b4-ehp0113-a0727b]. [@b7-ehp0113-a0727b] reported perchlorate and iodide levels in breast milk samples and noted that "if we take all the available data, there is no meaningful correlation between the perchlorate and iodide levels in breast milk." The study from Chile that Ginsberg and Rice refer to as [@b4-ehp0113-a0727b] is now published as [@b11-ehp0113-a0727b]. The study found that iodine nutrition of pregnant women in Chile is very similar to that in the United States. [@b11-ehp0113-a0727b] found no maternal or neonatal perchlorate-related thyroid effects or decreases in breast milk iodine with perchlorate doses spanning the 0.0007--0.007 mg/kg-day range.

[@b5-ehp0113-a0727b] argued that perchlorate database deficiencies require an additional uncertainty factor of 3--10 because of key data gaps, citing breast milk concerns and the extrapolation from a 14-day exposure study to chronic exposure. The NAS committee ([@b10-ehp0113-a0727b]) considered this and concluded that

> if inhibition of iodide uptake by the thyroid is duration-dependent, the effect should decrease rather than increase with time, because compensation would increase the activity of the sodium-iodide symporter and therefore increase iodide transport into the thyroid.

Evidence has subsequently shown this to be the case ([@b1-ehp0113-a0727b]).

The California EPA perchlorate risk assessment ([@b2-ehp0113-a0727b]) relied on the same studies as the NRC report ([@b10-ehp0113-a0727b]). The "point of departure" was based on iodine uptake inhibition by [@b6-ehp0113-a0727b], and a total uncertainty factor of 10 was applied to account for interindividual variability. After reviewing the NRC report ([@b10-ehp0113-a0727b]), the California EPA elected not to change its risk assessment or public health goal ([@b3-ehp0113-a0727b]).

In summary, the concerns presented by [@b5-ehp0113-a0727b] have already been addressed thoroughly by experts on perchlorate and thyroid toxicology and were found to be unsubstantiated. The NAS committee and other experts came to this conclusion based on a comprehensive review of the science in the field, not based entirely on an individual study, which has been mischaracterized by Ginsberg and Rice.

[^1]: Kerr-McGee Chemical LLC previously manufactured ammonium perchlorate at Henderson, Nevada, and currently is remediating perchlorate at that site. J.G. has co-authored several perchlorate studies, as has S.H.L. S.H.L. is a consultant to companies that manufacture and/or use perchlorates. A.E. works with S.H.L. at Consultants in Epidemiology & Occupational Health, LLC.
